Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Addex Therapeutics Ltd ADR (ADXN)

Addex Therapeutics Ltd ADR (ADXN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Addex Therapeutics Ltd ADR CHEMIN DES MINES 9 GENEVA V8 CH-1202 CHE

www.addextherapeutics.com/en P: 011-41-22-884-1555 F: +41 228841556

Description:

Addex Therapeutics Ltd is a clinical-stage pharmaceutical company. It is focused on the development and commercialization of small molecule drugs for neurological disorders. The company's lead drug candidate includes dipraglurant, ADX71149 which are in clinical stage. Its Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 PAM for neurodegenerative disorders. GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Addex Therapeutics Ltd is based in Geneva, Switzerland.

Key Statistics

Overview:

Market Capitalization, $K 8,752
Enterprise Value, $K 4,442
Shares Outstanding, K 1,060
Annual Sales, $ 1,800 K
Annual Net Income, $ -11,760 K
Last Quarter Sales, $ 270 K
Last Quarter Net Income, $ -3,530 K
EBIT, $ -9,750 K
EBITDA, $ -9,410 K
60-Month Beta 1.77
% of Insider Shareholders 15.00%
% of Institutional Shareholders 16.14%
Float, K 901
% Float 85.00%
Short Volume Ratio 0.64

Growth:

1-Year Return -29.88%
3-Year Return -95.56%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.37 on 06/06/24
Next Earnings Date 08/08/24
Earnings Per Share ttm -14.50
EPS Growth vs. Prev Qtr 66.26%
EPS Growth vs. Prev Year 73.65%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 10/23/23

ADXN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -364.25%
Return-on-Assets % -154.26%
Profit Margin % -653.33%
Debt/Equity 0.00
Price/Sales 4.81
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.48
Interest Coverage -29.95
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar